Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:RCKTNYSE:RCUSNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.80$7.45$5.90▼$34.11$569.33M2.191.45 million shs1.36 million shsRCKTRocket Pharmaceuticals$2.59-2.3%$5.02$2.19▼$26.98$282.98M0.682.15 million shs3.23 million shsRCUSArcus Biosciences$8.53-1.1%$8.80$6.50▼$18.98$912.73M0.83865,303 shs637,295 shsSMMTSummit Therapeutics$21.32+0.2%$23.47$6.78▼$36.91$15.80B-1.063.61 million shs1.40 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+4.42%+16.59%+2.77%-69.85%RCKTRocket Pharmaceuticals-2.26%-8.48%+11.16%-65.88%-87.83%RCUSArcus Biosciences-0.87%-0.11%-5.96%+4.41%-43.80%SMMTSummit Therapeutics+0.24%+5.75%-16.85%+4.92%+174.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.9429 of 5 stars4.34.00.00.02.22.51.3RCKTRocket Pharmaceuticals4.9558 of 5 stars4.24.00.04.72.85.01.3RCUSArcus Biosciences2.1165 of 5 stars4.40.00.00.01.81.70.0SMMTSummit Therapeutics3.0322 of 5 stars4.43.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29160.12% UpsideRCKTRocket Pharmaceuticals 2.41Hold$18.60618.15% UpsideRCUSArcus Biosciences 2.89Moderate Buy$21.29149.69% UpsideSMMTSummit Therapeutics 2.77Moderate Buy$35.0964.59% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, RCKT, RCUS, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.006/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.16N/AN/A$8.17 per share0.95RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ARCUSArcus Biosciences$258M3.50N/AN/A$5.30 per share1.61SMMTSummit Therapeutics$700K22,619.61N/AN/A$0.53 per share40.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest ARVN, RCKT, RCUS, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58RCKTRocket Pharmaceuticals0.059.199.19RCUSArcus Biosciences0.095.375.37SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%RCKTRocket Pharmaceuticals98.39%RCUSArcus Biosciences92.89%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%RCKTRocket Pharmaceuticals24.76%RCUSArcus Biosciences9.60%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableRCKTRocket Pharmaceuticals240106.79 million80.35 millionOptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableARVN, RCKT, RCUS, and SMMT HeadlinesRecent News About These CompaniesSummit Therapeutics Breaks Above 200-Day Moving Average - Bullish for SMMT - NasdaqJune 26 at 5:17 PM | nasdaq.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 22, 2025 | prnewswire.comWorld Equity Group Inc. Sells 14,062 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 22, 2025 | marketbeat.comGAMMA Investing LLC Purchases 15,331 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)June 21, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Downgraded to "Sell" Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Shares Sold by Five Pine Wealth ManagementJune 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 17, 2025 | prnewswire.comSummit Therapeutics SMMT Sees Institutional Growth on Nasdaq CompositeJune 17, 2025 | kalkinemedia.comKQ2 Earnings Forecast for SMMT Issued By Leerink PartnrsJune 17, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 16, 2025 | accessnewswire.comAAnalysts Offer Predictions for SMMT Q2 EarningsJune 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit ...June 15, 2025 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 15, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 13, 2025 | accessnewswire.comAPolianta Ltd Takes $1.17 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)June 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Up 5.1% - Time to Buy?June 12, 2025 | marketbeat.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 12, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Rating Increased to Strong Sell at Leerink PartnrsJune 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, RCKT, RCUS, and SMMT Company DescriptionsArvinas NASDAQ:ARVN$7.80 0.00 (0.00%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$7.86 +0.06 (+0.71%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Rocket Pharmaceuticals NASDAQ:RCKT$2.59 -0.06 (-2.26%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.60 +0.02 (+0.58%) As of 08:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Arcus Biosciences NYSE:RCUS$8.52 -0.10 (-1.10%) Closing price 06/26/2025 03:59 PM EasternExtended Trading$8.50 -0.03 (-0.29%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Summit Therapeutics NASDAQ:SMMT$21.32 +0.05 (+0.24%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$21.38 +0.06 (+0.28%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
